An attractive therapeutic target in BCP-ALL is the pan B-lymphocyte antigen CD19, a type I membrane protein of the immunoglobin superfamily that is expressed by the majority of B-lineage lymphoid malignancies [7,8,9,10]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.